Overview
CHDI Management provides administrative, management, and contracting services to CHDI Foundation and other non-profit organizations dedicated to Huntington’s disease (HD) research. It supports rapid discovery and development of HD therapies by handling operations so researchers can focus on science. The company’s work is service-based, not a product; its staff and offices enable global collaboration with academic and industry scientists. CHDI Management differentiates itself by its exclusive focus on Huntington’s disease and its role as the coordinating, nonprofit-backed management arm for HD research initiatives. Its goal is to increase understanding of HD and hasten the development of therapies to delay or slow the disease.
Work here?Claim your company
Simplify's Take
What believers are saying
- On May 26, 2026, Prilenia gave CHDI placebo-arm data from PRIDE and PROOF.
- At CHDI's February 2026 conference, AMT-130 showed 75% disease-slowing at three years.
- CHDI and Regeneron sequenced 18,874 Enroll-HD samples, expanding biomarker and genetics power.
What critics are saying
- CHDI depends on Huntington's disease breakthroughs; one field-wide setback freezes its mission.
- If donor funding tightens in 2027, CHDI's outsourced model loses operating leverage.
- Negative AMT-130 or SKY-0515 data would damage CHDI's core thesis and partner pipeline.
What makes CHDI Management unique
- CHDI is a privately funded nonprofit dedicated solely to Huntington's disease.
- Its virtual model outsources science while coordinating discovery, development, and data sharing.
- Enroll-HD plus whole-genome sequencing give CHDI unusually deep Huntington's datasets.
Help us improve and share your feedback! Did you find this helpful?